Prima names new advisors for CVac programs
Prima BioMed (ASX:PRR) has brought on two new senior clinical advisors for its CVac cancer vaccine development programs.
The new advisors are Dr Holbrook Kohrt, a professor of medicine at the oncology division of the Stanford University School of Medicine; and Dr Pamela Klein, founder and president of PMK BioResearch.
Drs Klein and Kohrt will work with Prima CTO Dr Sharron Gargosky and the rest of Prima’s management team to help guide the company’s CVac development strategy.
Together they will shape Prima’s ongoing clinical trials of CVac in ovarian cancer and help develop the clinical design for planned phase II pilot trials of CVac in additional cancer types.
“Drs Kohrt and Klein bring significant scientific knowledge and practical experience to the Prima team,” Dr Gargosky said. “I look forward to working with such esteemed professionals as we continue CVac development for ovarian cancer and look at potential applications in additional cancer targets.”
Prima enrolled the first patient in the ovarian cancer trial in the US in February last year and commenced recruitment in Europe last month. Preliminary results have been encouraging.
Prima Biomed shares were trading unchanged at $0.088 as of around 1 pm on Wednesday.
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
CTA granted for CAR-T cell therapy for multiple myeloma
The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...
